Indaptus Therapeutics Inc
Statements
Ratios
Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 15 | Q4 15 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 7,843.3 | 9,633.4 | 9,306.1 | 5,919.4 | 6,351.1 | 5,275.4 | 4,106.6 | 1,966.9 | – | – | – | |
| 35.6 | 48.6 | – | 3.6 | 2.5 | 2.3 | 3.4 | 1.9 | 2.9 | 4.7 | 5.5 | 4.1 | 1.4 | 1.6 | 0.6 | 1.1 | 0.0 | – | – | 0.5 | 0.9 | 1.3 | 1.0 | 0.7 | 0.7 | 0.5 | 0.8 | 0.9 | 1.5 | 1.3 | 2.0 | 2.9 | 1.9 | 2.4 | 2.8 | – | 0.6 | 2.0 | 15.8 | 30.6 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 965.5 | 4,633.8 | 5,572.5 | 2,145.1 | 2,471.8 | 2,669.0 | 4,364.5 | -1,990.2 | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.9 | 3.2 | 5.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -27.4% | -22.5% | -17.0% | -15.4% | -26.8% | -142.7% | -170.3% | -252.0% | -70.6% | -177.1% | 51.3% | 31.2% | 20.2% | -26.7% | -24.0% | -41.1% | -71.9% | -90.0% | -121.0% | -105.7% | -99.1% | -55.3% | -88.6% | -66.7% | -71.1% | -101.0% | -132.0% | -173.2% | -248.1% | -536.6% | -243.6% | -87.6% | -4.4% | |
| Margins | ||||||||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 33.4% | 11.9% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -849,505.9% | -822,953.7% | -854,780.6% | -797,397.0% | -1,045,289.2% | -1,088,100.1% | -1,111,765.2% | -1,078,189.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -799,972.6% | -776,810.7% | -816,758.9% | -772,497.9% | -1,021,906.6% | -1,071,277.6% | -1,153,838.9% | -1,147,449.9% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -695,296.4% | -642,093.1% | -661,345.8% | -597,997.2% | -838,312.1% | -913,867.6% | -1,018,645.6% | -1,055,490.7% | – | – | – | |
| Returns | ||||||||||||||||||||||||||||||||||||||||
| – | -20.1% | – | – | – | -49.2% | -72.0% | -53.8% | -63.0% | -81.3% | -98.6% | -120.9% | -306.8% | -412.6% | -263.7% | -188.2% | -64.2% | – | – | -24.7% | -13.8% | -21.5% | -31.4% | -45.3% | -50.4% | -58.2% | -71.8% | -78.5% | -98.3% | -127.7% | -160.0% | -255.4% | -248.1% | -380.8% | -562.5% | – | -366.2% | -661.5% | -1,511.2% | -135.6% | |
| – | -19.3% | – | – | – | -44.8% | -64.9% | -47.8% | -57.6% | -70.8% | -76.8% | -90.6% | -174.3% | -223.7% | -181.7% | -139.7% | -48.3% | -327.3% | -109.9% | -17.1% | -12.0% | -19.0% | -28.2% | -40.5% | -45.6% | -51.0% | -65.7% | -70.1% | -84.7% | -103.3% | -136.8% | -193.9% | -180.8% | -204.7% | -291.0% | -248.0% | -246.6% | -223.9% | -864.7% | -128.7% | |
| Balance Sheet & Debt | ||||||||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | -31 | -20 | -14 | -8.7 | -10 | -13 | -17 | -1.5 | -4.4 | -16 | – | -39 | -33 | -14 | -6.6 | -9.5 | -6.7 | -13 | -16 | -13 | -9.6 | -7.2 | -7.3 | -5.7 | -3.8 | 0.4 | -5.8 | – | – | – | |
| 93.8% | 95.6% | – | 87.7% | 95.4% | 91.1% | 90.1% | 88.8% | 91.4% | 87.1% | 77.9% | 74.9% | 56.8% | 54.2% | 68.9% | 74.3% | 75.2% | -13.4% | -15.5% | 69.4% | 86.8% | 88.5% | 89.9% | 89.3% | 90.5% | 87.8% | 91.5% | 89.4% | 86.2% | 80.9% | 85.5% | 75.9% | 72.9% | 53.8% | 51.7% | -24.5% | 67.3% | 33.9% | 57.2% | 94.9% | |
| – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | 0.0 | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | 0.0 | – | – | – | |
| Per Share | ||||||||||||||||||||||||||||||||||||||||
| – | -50.15 | – | – | – | -2,483.59 | -3,018.73 | -2,737.13 | -2,775.97 | -2,934.96 | -2,928.85 | -2,855.24 | -3,585.48 | -2,970.67 | -1,790.48 | -1,085.42 | -13,366.56 | -335.11 | -338.21 | -198.17 | -35.26 | -26.14 | -35.48 | -46.73 | -47.07 | -48.48 | -50.70 | -48.73 | -50.25 | -51.41 | -49.67 | -51.61 | -43.85 | -37.94 | -31.27 | -29.50 | -16.92 | -9.62 | -1.72 | -0.13 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 352.49 | 248.98 | – | 3,519.32 | 8,047.19 | 5,051.72 | 4,192.10 | 5,085.67 | 4,405.31 | 3,609.13 | 2,970.56 | 2,361.70 | 1,168.76 | 719.90 | 678.92 | 576.88 | 20,822.20 | -13.69 | -47.78 | 802.63 | 255.03 | 121.71 | 113.09 | 103.09 | 93.46 | 83.37 | 70.61 | 62.08 | 51.11 | 40.25 | 31.05 | 20.21 | 17.67 | 9.96 | 5.56 | -2.91 | 4.62 | 1.45 | 0.11 | 0.10 | |
| – | – | – | – | – | – | – | -2,697.45 | -2,870.06 | -2,861.94 | -2,523.56 | -2,579.81 | -2,330.12 | -1,907.67 | -1,112.20 | -448.22 | -997.87 | 201.24 | 153.72 | 79.07 | -58.35 | -38.29 | -46.06 | -52.34 | -55.42 | -50.84 | -56.21 | -52.74 | -43.39 | -44.68 | -41.06 | -41.79 | -33.94 | -31.12 | -26.67 | -26.05 | -15.56 | -7.06 | -1.58 | -0.13 | |
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.